Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Next Previous
X
Search
Trial Profile

A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oblimersen (Primary) ; Paclitaxel (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms ATG
  • Sponsors Genta (CEASED)

    • Most Recent Events

    • 17 May 2011 Results will be presented at ASCO-2011, according to a Genta media release.
    • 27 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Results were presented at ASCO 2010 (abstract no. 8561), according to an Abraxis BioScience media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top